Doctor profile · Federal record
Dr. Raja Devanathan, M.D.
Pulmonary Disease Physician (CMS: Pulmonary Disease) · Hobart, IN
- NPI 1871587220
- Accepts Medicare
- 44 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
7875 Grand Blvd
Hobart, IN 463426665
(219) 942-9658
fax (219) 947-1996
Credentials & registration
- NPI registered
- August 2005 — 21 yrs on file
- Profile last updated
- February 12, 2025
- Year of graduation
- 1982 — 44 yrs since
- Specialty taxonomy
- 207RP1001X — NUCC code
- State license (1)
- Indiana #01040141A
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1871587220. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
106,739
Distinct HCPCS
10
Medicare allowed
$3,842,923
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J2182 |
Injection, mepolizumab, 1 mg | 43,200 | 40 | $29 | |
J2356 |
Injection, tezepelumab-ekko, 1 mg | 31,710 | 20 | $18 | |
J2357 |
Injection, omalizumab, 5 mg | 20,559 | 30 | $38 | |
J0517 |
Injection, benralizumab, 1 mg | 4,920 | 29 | $167 | |
99232 |
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 1,412 | 341 | $74 | |
96401 |
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 1,192 | 119 | $65 | |
99212 |
Established patient office or other outpatient visit, 10-19 minutes | 856 | 526 | $52 | |
96372 |
Injection of drug or substance under skin or into muscle | 379 | 92 | $13 | |
99231 |
Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 346 | 86 | $45 | |
99222 |
Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 281 | 255 | $121 |
In context: peer comparison
Among 1 peers in Hobart Pulmonary Disease Physician, average services per provider: 2,884. This provider delivers 37× the peer median.Open Payments
Industry payments received
All-time total
$14,179
Transactions
36
Manufacturers
8
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| AstraZeneca Pharmaceuticals Lp | 8 | $7,970.14 | |
| GlaxoSmithKline, LLC. | 17 | $5,751.99 | |
| Inspire Medical Systems, INC. | 2 | $169.16 | |
| Sanofi-Aventis U.S. LLC | 1 | $94.95 | |
| Actelion Pharmaceuticals US, INC. | 1 | $78.99 | |
| Genentech USA, INC. | 2 | $68.46 | |
| Amgen INC. | 4 | $30.85 | |
| Fisher & Paykel Healthcare INC | 1 | $14.21 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
3,941
Patients
1,485
Total drug cost
$1,642,245
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Albuterol Sulfate Hfa (Albuterol Sulfate) | Brand | 740 | 282 | $36,558 |
| Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter) | Brand | 733 | 227 | $964,725 |
| Prednisone | Generic | 438 | 234 | $2,413 |
| Montelukast Sodium | Generic | 325 | 104 | $7,118 |
| Breo Ellipta (Fluticasone/Vilanterol) | Brand | 267 | 85 | $231,642 |
| Cefdinir | Generic | 210 | 153 | $3,091 |
| Pantoprazole Sodium | Generic | 166 | 61 | $1,939 |
| Symbicort (Budesonide/Formoterol Fumarate) | Brand | 159 | 44 | $125,590 |
| Ventolin Hfa (Albuterol Sulfate) | Brand | 156 | 47 | $17,403 |
| Roflumilast | Generic | 138 | 35 | $46,499 |
Hospital affiliations
Frequently asked questions
What is Dr. Raja Devanathan's medical specialty?
Dr. Raja Devanathan practices Pulmonary Disease Physician in Hobart, IN.
Where does Dr. Raja Devanathan practice?
Dr. Raja Devanathan practices at 7875 Grand Blvd, Hobart, IN 463426665. Office phone: 2199429658.
What is Dr. Raja Devanathan's NPI?
Dr. Raja Devanathan's National Provider Identifier (NPI) is 1871587220, issued by NPPES.
Does Dr. Raja Devanathan accept Medicare assignment?
Yes. Dr. Raja Devanathan accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Raja Devanathan commonly perform?
Top Medicare-reported procedures in 2023: Injection, mepolizumab, 1 mg (HCPCS J2182); Injection, tezepelumab-ekko, 1 mg (HCPCS J2356); Injection, omalizumab, 5 mg (HCPCS J2357). Source: CMS Medicare Physician & Other Practitioners file.